Flubromazolam’s job in clinical trials is restricted as a consequence of its classification being a designer drug. Even so, its effects are reversed from the benzodiazepine antagonist flumazenil in pharmacokinetic research, offering insights into its scientific implications and unexpected emergency management of overdoses.” the members in the

Article Under Review